| Overview |
| bs-12023R |
| GPR102 Polyclonal Antibody |
| WB, ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat, Cow, Sheep, Pig, Rabbit |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human G protein coupled receptor 102 |
| Polyclonal |
| #REF! |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4_. Store at -20_ for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| Cell membrane |
| G protein coupled receptor 102; G-protein coupled receptor 102; GPR102; TA5; TAAR8; TAAR8_HUMAN; TaR-5; TaR-8; TAR5; Trace amine assiciated receptor 8; Trace amine receptor 5; Trace amine receptor 8; Trace amine-associated receptor 8; TRAR5; GPCR GPR102. |
| Trace amines are endogenous molecules structurally related to classical biogenic amines that are linked to psychiatric conditions. A family of G-protein coupled receptors referred to as trace-amine-associated receptors (TAAR) are activated by trace amines and are present in very low levels in mammalian tissue. TaRs contain several structural features that are similar to the rhodopsin -adrenergic receptor superfamily, including the positions of the seven transmembrane regions that provide common ligand-binding pockets as well as the short N- and C-terminal domains. TAAR proteins are potential targets for drugs of abuse, such as amphetamine and MDMA, as well as neuropsychiatric disorders including schizophrenia, depression, and attention deficit disorder. |
| Application Dilution |
| WB |
1:300-5000 |
| ELISA |
1:500-1000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz